Click here to view online. Add this email to your safelist.

AstraZeneca logo

US FDA grants Fasenra Orphan Drug Designation for Eosinophilic Granulomatosis with Polyangiitis

26 November 2018

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Fasenra (benralizumab) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2018

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.